Exploring quality of life in patients with advanced thyroid cancer receiving targeted therapy
Health-related Quality of Life of Patients With Locally Advanced Thyroid Cancer Receiving Targeted Therapy
This study is testing how taking targeted cancer medications affects the quality of life for people with advanced thyroid cancer who may not be able to have surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Fujian Cancer Hospital Government |
| Drugs / interventions | anlotinib, lenvatinib |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT05824312 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the impact of tyrosine kinase inhibitors (TKIs) on health-related quality of life (HRQOL) in patients diagnosed with locally advanced thyroid cancer. Participants will complete quality of life questionnaires before surgery and at 1, 3, 6, and 12 months after starting TKI treatment. The study aims to determine whether these medications influence the overall well-being of patients who may not be eligible for radical surgery or are at risk of recurrence. By assessing HRQOL changes, the study seeks to provide insights into the effectiveness of TKIs beyond traditional clinical outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-70 with a diagnosis of locally advanced thyroid cancer who are receiving TKI drugs.
Not a fit: Patients who are pregnant, breastfeeding, or have a history of other malignant diseases or recent cardiovascular events may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of how TKIs affect the quality of life for patients with advanced thyroid cancer.
How similar studies have performed: While studies on TKIs in thyroid cancer exist, the specific focus on HRQOL in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients age (18-70 year old) * Diagnosis of locally advanced thyroid cancer * Patient receiving TKI drugs. Exclusion Criteria: * pregnancy or breastfeeding women; * history of other malignant diseases, unstable angina, myocardial infarction, cerebral infarction or cerebral hemorrhage within 6 months; (3) patients missing questionnaires greater than 3 times.
Where this trial is running
Fuzhou, Fujian
- Road Fuma No.420 — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Study coordinator: yu wu, doctor
- Email: dr_wuyu@fjzlhospital.com
- Phone: 13705003480
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.